Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B

Özdemir, Yusuf; Özdemir, Meryem; Bayramlar, Osman Faruk; Sürme, Serkan; Kaya, Sibel Yıldız; Karaali, Rıdvan; Balkan, İ̇lker İnanç; Mete, Bilgül; Saltoğlu, Neşe; Tabak, Fehmı

doi:10.1007/s11845-022-03066-y

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an Asian population, the annual incidence of HBsAg clearance was 0.33% -5.0% with antiviral treatments and 0.5% -2.66% without antiviral treatments (14)(15)(16)(17). In a study in Turkey, HBsAg seroclearance was developed in only 2 of 173 HBeAg-negative patients, and anti-HBs seroconversion was not determined (18). In the current study, HBsAg loss was seen in 1 patient who stopped treatment and in 2 patients who continued treatment, and anti-HBs seroconversion was developed in 2 patients who continued treatment.…”

Section: Discussionmentioning

confidence: 99%

The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

Akgül¹,

Arslan²,

Çelik³

et al. 2022

Hepat Mon

View full text Add to dashboard Cite

Background: Chronic hepatitis B (CHB) patients who are under the treatment of antiviral agents should be monitored in routine control visits. However, during the COVID-19 pandemic, the visits were interrupted. Objectives: This study aimed to investigate whether these patients were affected regarding clinical, laboratory, and treatment outcomes. Methods: This prospective study consisted of CHB patients aged > 18 who were applied to 3 tertiary centers between 14 February and 30 March 2022. The patients were selected from the ones who regularly applied to outpatient clinics and under the treatment of antiviral agents before the pandemic. The demographic and laboratory values, including serologic, biochemistry, and molecular results, were compared between the 2 groups who came and did not come to control visits. Results: A total number of 220 patients were included. More than half (n = 142, 64.5%) were female. The median age was 44 years (19 - 73). A hundred and forty-two (64.5%) patients did not come to control visits during the pandemic. The most common reason was anxiety about COVID-19. The tenofovir treatment was replaced with entecavir (ETV) due to osteopenia and with alafenamide due to osteopenia and/or renal failure. The previous agents were re-started in 27 (79.5%) patients who discontinued the treatment. Conclusions: The COVID-19 pandemic negatively impacted the follow-up of CHB patients. In this regard, 15.5% of patients stopped their treatments. The patients who stopped their follow-ups and continued tenofovir disoproxil fumarate (TDF) had proteinuria and decreases in bone mineral density (BMD) and estimated glomerular filtration rate (eGFR) levels.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

Akgül¹,

Arslan²,

Çelik³

et al. 2022

Hepat Mon

View full text Add to dashboard Cite

show abstract

Antivirals

2023

Reactions Weekly

View full text Add to dashboard Cite

Performance of Noninvasive Fibrosis Indices in Chronic Hepatitis B During Pretreatment and Post-Treatment Periods

Ozdemir,

Bayramlar

et al. 2023

Biomark. Med.

View full text Add to dashboard Cite

Background: Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. Method: This was a retrospective, single-center study. Results: The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for ≥F2, Fibrosis Index (FI; 0.703) for ≥F3; FI (0.872) for ≥F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for ≥F2; in FI based on four factors (FIB-4; 0.634) for ≥F3; in FIB-4 (0.678) for ≥F4 and in FIB-4 (0.814) for cirrhosis. Conclusion: FIB-4 and FI showed better performance in defining advanced fibrosis (≥F4) and cirrhosis.

show abstract

Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B

Cited by 3 publications

References 26 publications

The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study

Antivirals

Performance of Noninvasive Fibrosis Indices in Chronic Hepatitis B During Pretreatment and Post-Treatment Periods

Contact Info

Product

Resources

About